MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. SPOK
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Spok Holdings (SPOK) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Spok Holdings
NasdaqGS•Healthcare•Health Information Services
$10.71+0.03(<0.01%)Market closed
Market Cap
$223.00M
P/E
18.2x
P/S
1.6x
P/B
1.6x

Spok Holdings, Inc., through its subsidiary, Spok, Inc., engages in the healthcare communication solutions in the United States, Europe, Canada, Australia, Asia, and the Middle East. Its products and services enhance workflows for clinicians and support administrative compliance. The company delivers clinical information to care teams when and where it matters to enhance patient outcomes; and provides GenA Pager, a one-way alphanumeric pager. It offers subscriptions to one-way or two-way messaging services, as well as alphanumeric pagers that are configurable to support unencrypted or encrypted operation; and ancillary services, such as voicemail, and equipment loss or maintenance protection services, as well as sells devices to resellers who lease or resell them to their subscribers. The company provides Spok Care Connect suite products for contact centers, clinical alerting and notification, mobile communications and messaging, and public safety notifications. In addition, it provides professional, software license updates, and product support services, as well as sells third-party equipment. It serves businesses, professionals, management personnel, medical personnel, field sales personnel and service forces, members of the construction industry and construction trades, real estate brokers and developers, sales and services organizations, specialty trade organizations, manufacturing organizations, and government agencies. The company was formerly known as USA Mobility, Inc. and changed its name to Spok Holdings, Inc. in July 2014. Spok Holdings, Inc. was founded in 1986 and is headquartered in Plano, Texas.

C

How this company scores

AverageMetricSide Score: 54/100

Strongest: Cash & Earnings Quality (21/25); weakest: Growth (5/25).

Profitability13/25
Growth5/25
Balance Sheet & Red Flags15/25
Cash & Earnings Quality21/25
Strengths
Interest easily coveredCash-backed earningsConsistent free cash flowNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 18.2x5y range 6.2x – 21.7x
P/E 18.2x · near its 15-quarter median

Currently near its 15-quarter median.

P/S · 1.6x5y range 0.9x – 2.6x
P/S 1.6x · near its 20-quarter median

Currently near its 20-quarter median.

P/B · 1.6x5y range 0.8x – 2.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 20.5% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Revenue Decline

Watch

Revenue has softened, declining in 5 quarters. Watch for further erosion.

Price & Volume
Market Cap $223.00M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$135.97M
4Q
Q. Revenue
$35.01M
2%
TTM EBITDA
$19.81M
20%
TTM Op. Income
$16.17M
23%
Q. Op. Income
$5.42M
1%
TTM Net Income
$12.24M
4Q
Q. Net Income
$4.12M
9%
EPS
$0.2
9%
Shares Out.
$20.90M
7Q
$135.97M in TTM revenue declined 3.4% YoY, reaching $35.01M last quarter. TTM EBITDA of $19.81M and TTM operating income of $16.17M show growth is flowing through to the bottom line. TTM net income of $12.24M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has fallen for 4 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
18.1%
4%
Op. Margin
15.5%
3%
Net Margin
11.8%
8%
Op. margin of 15.5% is up 0.4% YoY — cost efficiency is improving. Net margin at 11.8% Over the past year, operating margin is up 3% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
18.2x
15%
P/S Ratio
1.6x
4Q
P/B Ratio
1.6x
4Q
At 18.2x P/E, the stock trades within typical market levels. P/S of 1.6x and P/B of 1.6x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 15% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$195.61M
6%
Cash
$16.59M
2Q
Long-Term Debt
N/A
Book Value
$139.87M
7Q
D/E Ratio
N/A
Debt/EBITDA
0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$6.48M
8%
TTM Free Cash Flow
$25.41M
0%
FCF Margin
18.7%
3Q
FCF / Net Income
2.1
3Q
TTM FCF of $25.41M on $6.48M in operating cash flow. The FCF / Net Income ratio of 2.1x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 0% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 1.6x
· near its 20-quarter median

Currently near its 20-quarter median.

Share Dilution

Watch

Shares outstanding rose 3.1% — mild dilution. Compare to earnings growth to assess the net per-share impact.